11 results on '"TOR, Yavuz Burak"'
Search Results
2. Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması.
- Author
-
Altınkaynak, Mustafa, Göksoy, Yağmur, Şenkal, Naci, Tor, Yavuz Burak, Akpınar, Timur, and Köse, Murat
- Abstract
Copyright of Sakarya Tıp Dergisi is the property of Sakarya Tip Dergisi and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
3. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score-matched cohort study
- Author
-
Mirioglu, Safak, primary, Dirim, Ahmet Burak, additional, Bektas, Murat, additional, Demir, Erol, additional, Tor, Yavuz Burak, additional, Ozluk, Yasemin, additional, Kilicaslan, Isin, additional, Oto, Ozgur Akin, additional, Yalcinkaya, Yasemin, additional, Caliskan, Yasar, additional, Artim-Esen, Bahar, additional, Yazici, Halil, additional, Inanc, Murat, additional, Turkmen, Aydin, additional, Gul, Ahmet, additional, and Sever, Mehmet Sukru, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score–matched cohort study.
- Author
-
Mirioglu, Safak, Dirim, Ahmet Burak, Bektas, Murat, Demir, Erol, Tor, Yavuz Burak, Ozluk, Yasemin, Kilicaslan, Isin, Oto, Ozgur Akin, Yalcinkaya, Yasemin, Caliskan, Yasar, Artim-Esen, Bahar, Yazici, Halil, Inanc, Murat, Turkmen, Aydin, Gul, Ahmet, and Sever, Mehmet Sukru
- Subjects
FAMILIAL Mediterranean fever ,KIDNEY transplantation ,INTERLEUKIN-1 ,BLOOD sedimentation ,COHORT analysis - Abstract
Background Data on use of interleukin (IL)-1 blockers in kidney transplant recipients (KTRs) with familial Mediterranean fever (FMF) are very limited. We aimed to evaluate the efficacy and safety of anakinra and canakinumab in the transplantation setting. Methods In this retrospective cohort study, we included KTRs who suffered from AA amyloidosis caused by FMF and treated with anakinra or canakinumab (study group, n = 36). Using propensity score matching, we selected 36 patients without FMF or amyloidosis from our database of 696 KTRs as the control group. Primary outcomes were patient and graft survival. Biopsy-confirmed graft rejection, changes in estimated glomerular filtration rate (eGFR), high-sensitivity CRP (hsCRP), erythrocyte sedimentation rate (ESR), proteinuria and number of monthly attacks were secondary outcomes. Results All KTRs with FMF began IL-1 blocker therapy with anakinra and nine (25%) were switched to canakinumab. Overall death was more frequent in the study group (19.4% vs 0%) (P = .005); however, overall graft loss was comparable between study (27.8%) and control groups (36.1%) (P = .448). Five- and 10-year graft survival rates were significantly higher in the study group (94.4% and 83.3%, respectively) than in the control group (77.8% and 63.9%, respectively) (P = .014 and P < .001, respectively). Rejections were numerically lower in study group (8.3% vs 25%), but it did not reach to statistical significance (P = .058). When compared with the pre-treatment period, with IL-1 blockers, the number of attacks per month (P < .001), and eGFR (P = .004), hsCRP (P < .001) and ESR (P = .026) levels were lower throughout the follow-up, whereas proteinuria levels were not. Conclusions Anakinra and canakinumab are effective in KTRs suffering from FMF; however, the mortality rate may be of concern. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Preliminary Criteria for Coronavirus Disease-19 Associated Pulmonary Macrophage Activation Syndrome: Analysis of Two Cohorts from Different Periods of the Pandemic
- Author
-
Amikishiyev, Shirkhan, primary, Gunver, Mehmet Guven, additional, Bektas, Murat, additional, Aghamuradov, Sarvan, additional, Ince, Burak, additional, Koca, Nevzat, additional, Torun, Ege Sinan, additional, Aliyeva, Numune, additional, Sari, Selma, additional, Çetin, Çigdem, additional, Dulundu, Banu Cicek Yalcin, additional, Deniz, Rabia, additional, Kemik, Fatih, additional, Agargun, Besim Fazil, additional, Gulseren, Ubeyde Ayse, additional, Besisik, Beliz, additional, Alkan, Onur, additional, Bağrıaçık, Ceren, additional, Tor, Yavuz Burak, additional, Senkal, Naci, additional, Catma, Yunus, additional, Durak, Gorkem, additional, Mese, Sevim, additional, Agacfidan, Ali, additional, Kose, Murat, additional, Erelel, Mustafa, additional, Çağatay, Arif Atahan, additional, Şimşek Yavuz, Serap, additional, Besısık, Sevgi Kalayoglu, additional, Esen, Figen, additional, and Gül, Ahmet, additional
- Published
- 2022
- Full Text
- View/download PDF
6. HIDDEN DANGER OF SARS-COV-2; MULTISYSTEM INFLAMMATORY SYNDROME IN ADULTS (MIS-A): FIRST CASE SERIES IN A SINGLE CENTER FROM TURKIYE.
- Author
-
BENLİ, Aysun, TOR, Yavuz Burak, ŞİMŞEK-YAVUZ, Serap, BAŞARAN, Seniha, ÇAĞATAY, Atahan, ÖZSÜT, Halit, GÜL, Ahmet, and ERAKSOY, Haluk
- Subjects
- *
MULTISYSTEM inflammatory syndrome , *LOW-molecular-weight heparin , *SARS-CoV-2 , *ADULTS , *PEPTIDES , *LYMPHOPENIA - Abstract
Objective: Multisystem Inflammatory Syndrome (MIS) is a condition seen in the early post-COVID-19 period and thought to develop with an impaired immune response. It has been usually reported in children but rarely in adults. Here we report the first adult MIS (MIS-A) case series from Turkiye. Material and Methods: Six patients who met the Centers for Disease Control and Prevention’s MIS-A diagnostic criteria were included in the study. The demographic, clinical, laboratory, radiological characteristics and therapy regimes and outcomes of the patients were recorded. Results: All of our cases had a history of mild COVID-19. They presented with fever, severe fatigue and hypotension. Abnormal echocardiography findings were detected in five patients. Only one patient had multiple mucocutaneous findings. Common laboratory features were lymphopenia, markedly increased C-Reaktive Protein, procalcitonin, pro-brain natriuretic peptide (pro-BNP), D-dimer, and ferritin. All patients had positive SARSCoV-2 antibody result. Corticosteroids and/or anakinra were used in five, and intravenous immunoglobulin was used in two patients. Low-molecular-weight heparin (LMWH) was used for all cases. Empirically initiated antibiotic treatments were discontinued after cultures were negative. After anti-inflammatory treatment, the hypotension of the patients resolved, they did not need intensive care follow-up and no mortality was seen in our cases. Conclusions: MIS-A is a severe and mortal condition that causes various clinical pictures and can be confused with sepsis. Anakinra, a recombinant IL-1 receptor antagonist, is a significant agent that can be used in the treatment of MIS-A since it blocks the cytokine cascade at an early stage. The satisfactory responses will be obtained with early diagnosis and anti-inflammatory treatment. In this period when the pandemic is not over yet, it is necessary to increase the awareness of clinicians about MIS-A, which can be fatal. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Initial complete blood count score and predicting disease progression in COVID-19 patients
- Author
-
Ozbalak, Murat, Besisik, Sevgi Kalayoglu, Tor, Yavuz Burak, Medetalibeyoglu, Alpay, Kose, Murat, Senkal, Naci, Aksoy, Elif, Cagatay, Atahan, Erelel, Mustafa, Ahmet Gül, Esen, Figen, Yavuz, Serap Simsek, Alkac, Ummuhan Isoglu, and Tukek, Tufan
- Subjects
Original Article - Abstract
Introduction: Coronavirus has caused a pandemic since it was first detected in Wuhan in December 2019. The mortality rate is high in moderate and severe cases. Our study aimed to screen the CBC parameters as a useful predictive factor for COVID-19 resulting in critical illness. Methods: A total of 285 patients with positive PCR results were analyzed. The median age was 55 (24-90), and 64.2% of patients were male. Sixty-eight percent of cases were hospitalized with moderate, 32% with severe disease at initial admission. Results: We found that lymphocyte count 6, and platelet to lymphocyte ratio (PLR) >350 were predictive of the outcome. We scored our cohort 0-3 for these three parameters. Patients with a score of 2-3 were more likely to have progressive disease, anti-cytokine treatment, intensive care admission, intubation, and death, compared to patients with a score of 0-1. Additionally, they tended to be hospitalized for longer (median 11.5 days, mean 15.6), compared to those with a score 0 or 1 (median 9 days, mean 11.3). Twenty-eight of 38 cases with scores of 2-3 were discharged (73.6%), whereas the rate was 89% for patients with a score of 0-1 (P=0.009). Conclusion: Based on the absolute lymphocyte count (6, PLR >350), our three-parameter score was able to predict disease progression, and the likelihood of anti-cytokine treatment, intubation, and death. We think that COVID-19 patients presenting with moderate to severe pneumonia, and having scores of 2 or 3 on our scale, should be closely monitored and robustly supported.
- Published
- 2020
8. COVID-19-ilişkili makrofaj aktivasyon sendromu için sınıflandırma kriterleri geliştirilmesi.
- Author
-
Amikishiyev, Shirkhan, Günver, Mehmet Güven, Bektaş, Murat, Aghamuradov, Sarvan, İnce, Burak, Koca, Nevzat, Torun, Ege Sinan, Aliyeva, Numune, Sarı, Selma, Çetin, Çiğdem, Dulundu, Banu Çiçek Yalçın, Deniz, Rabia, Kemik, Fatih, Ağargün, Besim Fazıl, Gülseren, Übeyde Ayşe, Beşışık, Beliz, Alkan, Onur, Tor, Yavuz Burak, Şenkal, Naci, and Durak, Görkem
- Abstract
Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
9. Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
- Author
-
Amikishiyev, Shirkhan, Mehmet Guven Gunver, Bektas, Murat, Aghamuradov, Sarvan, Ince, Burak, Koca, Nevzat, Torun, Ege Sinan, Aliyeva, Numune, Sari, Selma, Cetin, Cigdem, Dulundu, Banu Cicek Yalcin, Deniz, Rabia, Kemik, Fatih, Agargun, Besim Fazil, Gulseren, Ubeyde Ayse, Besisik, Beliz, Alkan, Onur, Bagriacik, Ceren, Tor, Yavuz Burak, Senkal, Naci, Catma, Yunus, Durak, Gorkem, Mese, Sevim, Agacfidan, Ali, Kose, Murat, Erelel, Mustafa, Cagatay, Arif Atahan, Besisik, Sevgi Kalayoglu, Esen, Figen, and Gul, Ahmet
10. Dipyridamole does not have any additive effect on the prevention of COVID-19 coagulopathy.
- Author
-
Kalayoglu Besisik S, Ozbalak M, Tor YB, Medetalibeyoglu A, Kose M, Senkal N, Cagatay A, Erelel M, Gul A, Esen F, Simsek Yavuz S, Eraksoy H, and Tukek T
- Abstract
Objective: Severe acute respiratory syndrome (SARS) coronavirus 2 (SaRS-Cov-2) associated respiratory disease (COVID-19), announced as a pandemic, is a multisystem syndrome. SARS-CoV-2 directly infects and damages vascular endothelial cells, which leads to microvascular dysfunction and promotes a procoagulant state. Dipyridamole (DP) acts as a reversible phosphodiesterase inhibitor and is used mainly as an antiplatelet agent. It is hypothetised that it has possible activities in COVID-19., Design and Methodology: We report our retrospective, real-world results of DP added to low-molecular weight heparin (LMWH) in the treatment of 462 clinically diagnosed and hospitalized COVID-19 patients. We compared anticoagulation with and without DP addition with no administration of anticoagulation in the same time frame. The primary outcome was proven or highly suspected coagulopathy within 30 days of hospitalization., Results: Definitive coagulopathy has been diagnosed in 3 (3.5%) of 85 LMWH administered patients and 7 (2.13%) of 328 DP + LMWH received patients (P=0.456). Five cases with definitive coagulopathy were not initiated any anticoagulation at the time of the event. The multivariate analysis showed that DP addition to the anticoagulant approach did not have any impact on the risk of demonstrated coagulopathy and highly-suspected coagulopathy., Conclusion: We think that our clinical experience is valuable in showing the real-life results of DP + LMWH treatment in COVID-19. This approach did not affect the coagulopathy rate. Our data did also not document an additive effect of DP in the COVID-19 outcome. Prospective controlled trials would give more convincing results regarding the role of DP in COVID-19 endothelial dysfunction and clinical outcome., Competing Interests: None., (AJBR Copyright © 2022.)
- Published
- 2022
11. Initial complete blood count score and predicting disease progression in COVID-19 patients.
- Author
-
Ozbalak M, Kalayoglu Besisik S, Tor YB, Medetalibeyoglu A, Kose M, Senkal N, Aksoy E, Cagatay A, Erelel M, Gul A, Esen F, Simsek Yavuz S, Isoglu Alkac U, and Tukek T
- Abstract
Introduction: Coronavirus has caused a pandemic since it was first detected in Wuhan in December 2019. The mortality rate is high in moderate and severe cases. Our study aimed to screen the CBC parameters as a useful predictive factor for COVID-19 resulting in critical illness., Methods: A total of 285 patients with positive PCR results were analyzed. The median age was 55 (24-90), and 64.2% of patients were male. Sixty-eight percent of cases were hospitalized with moderate, 32% with severe disease at initial admission., Results: We found that lymphocyte count <620/mcl, neutrophil-to-lymphocyte ratio (NLR) >6, and platelet to lymphocyte ratio (PLR) >350 were predictive of the outcome. We scored our cohort 0-3 for these three parameters. Patients with a score of 2-3 were more likely to have progressive disease, anti-cytokine treatment, intensive care admission, intubation, and death, compared to patients with a score of 0-1. Additionally, they tended to be hospitalized for longer (median 11.5 days, mean 15.6), compared to those with a score 0 or 1 (median 9 days, mean 11.3). Twenty-eight of 38 cases with scores of 2-3 were discharged (73.6%), whereas the rate was 89% for patients with a score of 0-1 (P=0.009)., Conclusion: Based on the absolute lymphocyte count (<620/mcl, NLR >6, PLR >350), our three-parameter score was able to predict disease progression, and the likelihood of anti-cytokine treatment, intubation, and death. We think that COVID-19 patients presenting with moderate to severe pneumonia, and having scores of 2 or 3 on our scale, should be closely monitored and robustly supported., Competing Interests: None., (AJBR Copyright © 2021.)
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.